Rare pulmonary disease and orphan drugs: a path to the future

Rare pulmonary disease and orphan drugs: a path to the future

Bibliographic Details
Main Authors:	Sergio Harari, Yochai Adir, Marc Humbert
Format:	Article
Language:	English
Published:	European Respiratory Society 2019-10-01
Series:	European Respiratory Review
Online Access:	http://err.ersjournals.com/content/28/153/190115.full

Similar Items

Global effort against rare and orphan diseases
by: Marc Humbert, et al.
Published: (2012-09-01)

Future perspectives on rare pulmonary diseases and rare presentations of common disorders
by: Sergio Harari, et al.
Published: (2013-09-01)

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
by: Sergio Harari, et al.
Published: (2015-09-01)

Rare pulmonary diseases: a common fight
by: Sergio Harari, et al.
Published: (2017-09-01)

Pulmonary hypertension in patients with chronic myeloproliferative disorders
by: Yochai Adir, et al.
Published: (2015-09-01)

Rare diseases and orphan drugs
by: Domenica Taruscio, et al.
Published: (2011-01-01)

Ultra-rare disease: an European perspective
by: Sergio Harari, et al.
Published: (2020-07-01)

Pulmonary hypertension: a paradigm for rare pulmonary diseases
by: Sergio Harari
Published: (2017-12-01)

Pricing of orphan drugs in oncology and rare diseases
by: Mark Nuijten, et al.
Published: (2020-01-01)

Rare or orphan diseases: more orphan than rare in Peru
by: Frank Lizaraso Caparó, et al.
Published: (2018-08-01)

Orphan diseases — rare but important!
by: article Editorial
Published: (2019-06-01)

Orphan diseases — rare but important!
by: article Editorial
Published: (2019-06-01)

Financing rare or orphan diseases
by: Alfredo Oyola-García, et al.
Published: (2014-12-01)

EVALUATION OF PHARMACISTS’ KNOWLEDGE AND ATTITUDES REGARDING RARE DISEASES AND ORPHAN DRUGS
by: Dušanka Krajnović, et al.
Published: (2013-01-01)

Ethical questions linked to rare diseases and orphan drugs - A systematic review
by: Kacet, Jaroslav, et al.
Published: (2020)

Rare Diseases and Difficulty Accessing Orphan Drugs: A Topic That Needs Discussion
by: José Pedro Vieira
Published: (2021-04-01)

From Rare to Neglected Diseases: A Sustainable and Inclusive Healthcare Perspective for Reframing the Orphan Drugs Issue
by: Marialuisa Saviano, et al.
Published: (2019-03-01)

Ethical Questions Linked to Rare Diseases and Orphan Drugs – A Systematic Review
by: Kacetl J, et al.
Published: (2020-10-01)

Educational aspects of rare and orphan lung diseases
by: Tiago M. Alfaro, et al.
Published: (2021-03-01)

New functionalities in Orphanet for orphan drugs, R&D and marketing authorisations to better serve the rare diseases community
by: Aymé Ségolène, et al.
Published: (2010-10-01)

Financing drug discovery for orphan diseases
by: Gromatzky, Austin A., et al.
Published: (2014)

The European Respiratory Review: continuing the success and targeting new challenges
by: Yochai Adir
Published: (2019-02-01)

Financing for rare or orphan diseases, a thing to do
by: Akram Hernández-Vásquez, et al.
Published: (2014-07-01)

A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
by: Marcin Czech, et al.
Published: (2020-01-01)

Dynamics of patents, orphan drug designation, licensing, and revenues from drugs for rare diseases: The market expansion of eculizumab.
by: Rosângela Caetano, et al.
Published: (2021-01-01)

Path of a patient with a rare diagnosis: regulatory documents and organization of the process of treatment and diagnosis of an orphan disease in the Russian Federation
by: S. I. Kutsev
Published: (2018-01-01)

DRUG FLURENISID AS AN IMMUNOMODULATOR FOR THE TREATMENT OF ORPHAN DISEASES
by: Мaria Kovalenko
Published: (2017-12-01)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
by: Kim Hendrickx, et al.
Published: (2021-09-01)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
by: Kavisha Jayasundara, et al.
Published: (2019-01-01)

To what degree are orphan drugs patient-centered? A review of the current state of clinical research in rare diseases
by: Sally Lanar, et al.
Published: (2020-06-01)

Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
by: Kathleen L. Miller, et al.
Published: (2021-06-01)

Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy
by: Sonali Bhattacharjee, et al.
Published: (2018-09-01)

Cancer cachexia: an orphan with a future
by: Mitja Lainscak, et al.
Published: (2019-02-01)

Why we should care about ultra-rare disease
by: Sergio Harari
Published: (2016-06-01)

Patients with rare diseases: from therapeutic orphans to pioneers of personalized treatments
by: Christoph Klein, et al.
Published: (2018-01-01)

Predictors of orphan drug approval
by: Heemstra Harald
Published: (2010-10-01)

Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
by: Pejčić Ana V., et al.
Published: (2016-01-01)

Water lily or Camelotte sign in pulmonary hydatid cyst − an orphan disease
by: Sudheer Tale, et al.
Published: (2019-01-01)

Evaluating health policy and legal responses : how to reduce barriers and improve access to orphan drugs for rare diseases in Canada
by: Blais, Catherine-Marie
Published: (2016)

Orphan drugs for the pathogenetic treatment of rаre diseases in the drug registry
by: S. A. Mishinova
Published: (2019-04-01)